We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck KGaA (MKGAF) Q2 Earnings Down Y/Y, Sales Flat
Read MoreHide Full Article
Merck KGaA (MKGAF - Free Report) is a science and technology company specializing in the fields of healthcare, life science and performance materials. The company's portfolio comprises a wide array of products ranging from innovative pharmaceuticals and biopharmaceuticals to life science tools, specialty chemicals and high-tech materials.
The company is focused on oncology, multiple sclerosis, infertility, growth disorders, selected cardiovascular and metabolic diseases, women’s and children’s health, cough and cold as well as everyday health protection.
The company reports its results in three business sectors – Healthcare, Life Science and Performance Materials.
We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: The company’s second-quarter 2018 earnings per American Depositary Receipt (ADR) declined 11.6% year over year to $1.47.
Revenue: The company posted revenues of €3.7 billion ($4.4 billion) in the reported quarter, down a mere 0.5% mainly due to unfavorable currency movement of 4.7%. The Healthcare and Life Science segment continues to drive the company’s organic growth.
Key Stats: The company’s new drugs – Bavencio and Mavenclad – continues to show strong growth with sales of €17 million and €20 million, respectively, in the quarter.
2018 Guidance: For 2018, the company increased its net sales guidance to be in the range of €14.1 billion to €14.6 billion from previous outlook of €14 billion to €14.5 billion. However, the company now expects currency movements to have an unfavourable impact of 3% to 5% on EBIDTA compared to previous 4% to 6%.
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Merck KGaA (MKGAF) Q2 Earnings Down Y/Y, Sales Flat
Merck KGaA (MKGAF - Free Report) is a science and technology company specializing in the fields of healthcare, life science and performance materials. The company's portfolio comprises a wide array of products ranging from innovative pharmaceuticals and biopharmaceuticals to life science tools, specialty chemicals and high-tech materials.
The company is focused on oncology, multiple sclerosis, infertility, growth disorders, selected cardiovascular and metabolic diseases, women’s and children’s health, cough and cold as well as everyday health protection.
The company reports its results in three business sectors – Healthcare, Life Science and Performance Materials.
We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: The company’s second-quarter 2018 earnings per American Depositary Receipt (ADR) declined 11.6% year over year to $1.47.
Revenue: The company posted revenues of €3.7 billion ($4.4 billion) in the reported quarter, down a mere 0.5% mainly due to unfavorable currency movement of 4.7%. The Healthcare and Life Science segment continues to drive the company’s organic growth.
Key Stats: The company’s new drugs – Bavencio and Mavenclad – continues to show strong growth with sales of €17 million and €20 million, respectively, in the quarter.
2018 Guidance: For 2018, the company increased its net sales guidance to be in the range of €14.1 billion to €14.6 billion from previous outlook of €14 billion to €14.5 billion. However, the company now expects currency movements to have an unfavourable impact of 3% to 5% on EBIDTA compared to previous 4% to 6%.
Merck KGaA Price and EPS Surprise
Merck KGaA Price and EPS Surprise | Merck KGaA Quote
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>